Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head ContrastDefense World · Aug 24, 2026
Monopar Appoints Jeffrey D. Kent, M.D.GlobeNewsWire · Aug 19, 2026
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'Seeking Alpha · Aug 18, 2026
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More247 Wallst · Aug 13, 2026
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire · Aug 12, 2026Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.64 | -$0.62 | Beat |
| May 14, 2026 | -$1.06 | -$0.46 | Beat |
| Mar 27, 2026 | -$0.51 | -$0.61 | Miss |
| Nov 13, 2025 | -$0.46 | -$0.48 | Miss |
| Aug 12, 2025 | -$0.47 | -$0.35 | Beat |
| May 13, 2025 | -$0.65 | -$0.38 | Beat |